Advertisement
14-04-2025 | Carbapenem Antibiotic | Review Article
Management of Carbapenem Resistant Gram-Negative Infections
Published in: Indian Journal of Pediatrics
Login to get accessPlease log in to get access to this content
Literature
1.
go back to reference World Health Organization. WHO Bacterial Priority Pathogens List. 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance, 17th May 2024. Available at: https://iris.who.int/bitstream/handle/10665/376776/9789240093461-eng.pdf?sequence=1. Accessed November 11, 2024.
World Health Organization. WHO Bacterial Priority Pathogens List. 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance, 17th May 2024. Available at: https://iris.who.int/bitstream/handle/10665/376776/9789240093461-eng.pdf?sequence=1. Accessed November 11, 2024.
2.
go back to reference Lutgring JD. Carbapenem-resistant enterobacteriaceae: an emerging bacterial threat. Semin Diagn Pathol. 2019;36:182–6.CrossRefPubMed
Lutgring JD. Carbapenem-resistant enterobacteriaceae: an emerging bacterial threat. Semin Diagn Pathol. 2019;36:182–6.CrossRefPubMed
3.
go back to reference Annual Report January 2023 to December 2023. Antimicrobial Resistance Research and Surveillance Network. Indian Council of Medical Research. Division of Descriptive Research. Available at: https://www.icmr.gov.in/icmrobject/uploads/Documents/1725536060_annual_report_2023.pdf. Accessed 11 Nov 2024.
Annual Report January 2023 to December 2023. Antimicrobial Resistance Research and Surveillance Network. Indian Council of Medical Research. Division of Descriptive Research. Available at: https://www.icmr.gov.in/icmrobject/uploads/Documents/1725536060_annual_report_2023.pdf. Accessed 11 Nov 2024.
4.
go back to reference Richter SE, Miller L, Needleman J, et al. Risk factors for development of carbapenem resistance among gram-negative rods. Open Forum Infect Dis. 2019;6:ofz027.CrossRefPubMedPubMedCentral
Richter SE, Miller L, Needleman J, et al. Risk factors for development of carbapenem resistance among gram-negative rods. Open Forum Infect Dis. 2019;6:ofz027.CrossRefPubMedPubMedCentral
5.
go back to reference Palacios-Baena ZR, Giannella M, Manissero D, et al. Risk factors for carbapenem-resistant Gram-negative bacterial infections: A systematic review. Clin Microbiol Infect. 2021;27:228–35.CrossRefPubMed
Palacios-Baena ZR, Giannella M, Manissero D, et al. Risk factors for carbapenem-resistant Gram-negative bacterial infections: A systematic review. Clin Microbiol Infect. 2021;27:228–35.CrossRefPubMed
6.
go back to reference Bonardi S, Pitino R. Carbapenemase-producing bacteria in food-producing animals, wildlife and environment: A challenge for human health. Ital J Food Saf. 2019;8:7956.PubMedPubMedCentral
Bonardi S, Pitino R. Carbapenemase-producing bacteria in food-producing animals, wildlife and environment: A challenge for human health. Ital J Food Saf. 2019;8:7956.PubMedPubMedCentral
7.
go back to reference Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria. Clin Infect Dis. 2019;69:S521–8.CrossRefPubMedPubMedCentral
Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria. Clin Infect Dis. 2019;69:S521–8.CrossRefPubMedPubMedCentral
8.
go back to reference Periasamy H, Joshi P, Palwe S, Shrivastava R, Bhagwat S, Patel M. High prevalence of Escherichia coli clinical isolates in India harbouring four amino acid inserts in PBP3 adversely impacting activity of aztreonam/avibactam. J Antimicrob Chemother. 2020;75:1650–1.CrossRefPubMed
Periasamy H, Joshi P, Palwe S, Shrivastava R, Bhagwat S, Patel M. High prevalence of Escherichia coli clinical isolates in India harbouring four amino acid inserts in PBP3 adversely impacting activity of aztreonam/avibactam. J Antimicrob Chemother. 2020;75:1650–1.CrossRefPubMed
9.
go back to reference D’Onofrio V, Salimans L, Bedenić B, Cartuyvels R, Barišić I, Gyssens IC. The clinical impact of rapid molecular Microbiological diagnostics for pathogen and resistance gene identification in patients with sepsis: A systematic review. Open Forum Infect Dis. 2020;7:ofaa352.CrossRefPubMedPubMedCentral
D’Onofrio V, Salimans L, Bedenić B, Cartuyvels R, Barišić I, Gyssens IC. The clinical impact of rapid molecular Microbiological diagnostics for pathogen and resistance gene identification in patients with sepsis: A systematic review. Open Forum Infect Dis. 2020;7:ofaa352.CrossRefPubMedPubMedCentral
10.
go back to reference Division of Epidemiology and Communicable Diseases. Indian Council of Medical Research. Guidance on Diagnosis and Management of Carbapenem Resistant Gram-Negative Infections, March 2022. Available at: https://www.icmr.gov.in/icmrobject/custom_data/pdf/resource-guidelines/Diagnosis_and_management_of_CROs.pdf. Accessed February 7, 2025.
Division of Epidemiology and Communicable Diseases. Indian Council of Medical Research. Guidance on Diagnosis and Management of Carbapenem Resistant Gram-Negative Infections, March 2022. Available at: https://www.icmr.gov.in/icmrobject/custom_data/pdf/resource-guidelines/Diagnosis_and_management_of_CROs.pdf. Accessed February 7, 2025.
11.
go back to reference Rajendran S, Gopalakrishnan R, Tarigopula A, et al. Xpert Carba-R assay on flagged blood culture samples: clinical utility in intensive care unit patients with bacteremia caused by Enterobacteriaceae. Indian J Crit Care Med. 2023;27:655–62.CrossRefPubMedPubMedCentral
Rajendran S, Gopalakrishnan R, Tarigopula A, et al. Xpert Carba-R assay on flagged blood culture samples: clinical utility in intensive care unit patients with bacteremia caused by Enterobacteriaceae. Indian J Crit Care Med. 2023;27:655–62.CrossRefPubMedPubMedCentral
12.
go back to reference Zengin Canalp H, Bayraktar B. Direct rapid identification from positive blood cultures by MALDI-TOF MS: specific focus on turnaround times. Microbiol Spectr. 2021;9:e0110321.CrossRefPubMed
Zengin Canalp H, Bayraktar B. Direct rapid identification from positive blood cultures by MALDI-TOF MS: specific focus on turnaround times. Microbiol Spectr. 2021;9:e0110321.CrossRefPubMed
13.
go back to reference Vineeth VK, Nambi PS, Gopalakrishnan R, et al. Clinical utility of blood culture identification 2 panel in flagged blood culture samples from the intensive care unit of a tertiary care hospital. Indian J Crit Care Med. 2024;28:461–6.CrossRefPubMedPubMedCentral
Vineeth VK, Nambi PS, Gopalakrishnan R, et al. Clinical utility of blood culture identification 2 panel in flagged blood culture samples from the intensive care unit of a tertiary care hospital. Indian J Crit Care Med. 2024;28:461–6.CrossRefPubMedPubMedCentral
14.
go back to reference Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: Lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322–8.CrossRefPubMedPubMedCentral
Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: Lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322–8.CrossRefPubMedPubMedCentral
15.
go back to reference Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024. https://doi.org/10.1093/cid/ciae403. Epub ahead of print.CrossRefPubMed
Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024. https://doi.org/10.1093/cid/ciae403. Epub ahead of print.CrossRefPubMed
16.
go back to reference Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect. 2022;28:521–47.CrossRefPubMed
Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect. 2022;28:521–47.CrossRefPubMed
17.
go back to reference Cprek JB, Gallagher JC. Ertapenem-containing double-carbapenem therapy for treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2015;60:669–73.CrossRefPubMedPubMedCentral
Cprek JB, Gallagher JC. Ertapenem-containing double-carbapenem therapy for treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2015;60:669–73.CrossRefPubMedPubMedCentral
18.
go back to reference Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 2014;59:88–94.CrossRefPubMedPubMedCentral
Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 2014;59:88–94.CrossRefPubMedPubMedCentral
19.
go back to reference CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 34th ed. CLSI Supplement M100. Clinical and Laboratory Standards Institute; 2024.
CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 34th ed. CLSI Supplement M100. Clinical and Laboratory Standards Institute; 2024.
20.
go back to reference Khan A, Erickson SG, Pettaway C, Arias CA, Miller WR, Bhatti MM. Evaluation of susceptibility testing methods for Aztreonam and ceftazidime-avibactam combination therapy on extensively drug-resistant gram-negative organisms. Antimicrob Agents Chemother. 2021;65:e0084621.CrossRefPubMed
Khan A, Erickson SG, Pettaway C, Arias CA, Miller WR, Bhatti MM. Evaluation of susceptibility testing methods for Aztreonam and ceftazidime-avibactam combination therapy on extensively drug-resistant gram-negative organisms. Antimicrob Agents Chemother. 2021;65:e0084621.CrossRefPubMed
21.
go back to reference Prayag PS, Patwardhan SA, Panchakshari S, et al. Ceftazidime-avibactam with or without aztreonam vs polymyxin-based combination therapy for carbapenem-resistant enterobacteriaceae: A retrospective analysis. Indian J Crit Care Med. 2023;27:444–50.CrossRefPubMedPubMedCentral
Prayag PS, Patwardhan SA, Panchakshari S, et al. Ceftazidime-avibactam with or without aztreonam vs polymyxin-based combination therapy for carbapenem-resistant enterobacteriaceae: A retrospective analysis. Indian J Crit Care Med. 2023;27:444–50.CrossRefPubMedPubMedCentral
22.
go back to reference Chen J, Hu Q, Zhou P, Deng S. Ceftazidime–avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: A systematic review and meta-analysis. Infection. 2024;52:19–28.CrossRefPubMed
Chen J, Hu Q, Zhou P, Deng S. Ceftazidime–avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: A systematic review and meta-analysis. Infection. 2024;52:19–28.CrossRefPubMed
23.
go back to reference Heffernan AJ, Sime FB, Sun J, et al. β-lactam antibiotic versus combined β-lactam antibiotics and single daily dosing regimens of aminoglycosides for treating serious infections: A meta-analysis. Int J Antimicrob Agents. 2020;55:105839.CrossRefPubMed
Heffernan AJ, Sime FB, Sun J, et al. β-lactam antibiotic versus combined β-lactam antibiotics and single daily dosing regimens of aminoglycosides for treating serious infections: A meta-analysis. Int J Antimicrob Agents. 2020;55:105839.CrossRefPubMed
24.
go back to reference Clinical and Laboratory Standards Institute. AST News Update June. 2023: New! CLSI M100-Ed33: Updated Aminoglycoside Breakpoints for Enterobacterales and Pseudomonas aeruginosa. Available at: https://clsi.org/about/blog/ast-news-update-june-2023-new-clsi-m100-ed33-updated-aminoglycoside-breakpoints-for-enterobacterales-and-pseudomonas-aeruginosa/. Accessed November 11, 2024.
Clinical and Laboratory Standards Institute. AST News Update June. 2023: New! CLSI M100-Ed33: Updated Aminoglycoside Breakpoints for Enterobacterales and Pseudomonas aeruginosa. Available at: https://clsi.org/about/blog/ast-news-update-june-2023-new-clsi-m100-ed33-updated-aminoglycoside-breakpoints-for-enterobacterales-and-pseudomonas-aeruginosa/. Accessed November 11, 2024.
25.
go back to reference Sader HS, Mendes RE, Kimbrough JH, Kantro V, Castanheira M. Impact of the recent clinical and laboratory standards Institute breakpoint changes on the antimicrobial spectrum of aminoglycosides and the activity of Plazomicin against multidrug-resistant and carbapenem-resistant enterobacterales from United States medical centers. Open Forum Infect Dis. 2023;10:ofad058.CrossRefPubMedPubMedCentral
Sader HS, Mendes RE, Kimbrough JH, Kantro V, Castanheira M. Impact of the recent clinical and laboratory standards Institute breakpoint changes on the antimicrobial spectrum of aminoglycosides and the activity of Plazomicin against multidrug-resistant and carbapenem-resistant enterobacterales from United States medical centers. Open Forum Infect Dis. 2023;10:ofad058.CrossRefPubMedPubMedCentral
26.
go back to reference Pragasam AK, Jennifer SL, Solaimalai D, et al. Expected plazomicin susceptibility in India based on the prevailing aminoglycoside resistance mechanisms in gram-negative organisms derived from whole-genome sequencing. Indian J Med Microbiol. 2020;38:313–8.CrossRefPubMed
Pragasam AK, Jennifer SL, Solaimalai D, et al. Expected plazomicin susceptibility in India based on the prevailing aminoglycoside resistance mechanisms in gram-negative organisms derived from whole-genome sequencing. Indian J Med Microbiol. 2020;38:313–8.CrossRefPubMed
27.
go back to reference Food and Drug Administration. FDA Drug Safety Communication: Increased Risk of Death with Tygacil (Tigecycline) Compared to Other Antibiotics used to Treat Similar Infections, May 2010. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-antibiotics. Accessed November 11, 2024.
Food and Drug Administration. FDA Drug Safety Communication: Increased Risk of Death with Tygacil (Tigecycline) Compared to Other Antibiotics used to Treat Similar Infections, May 2010. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-antibiotics. Accessed November 11, 2024.
28.
go back to reference De Pascale G, Montini L, Pennisi M, et al. High dose Tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014;18:R90.CrossRefPubMedPubMedCentral
De Pascale G, Montini L, Pennisi M, et al. High dose Tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014;18:R90.CrossRefPubMedPubMedCentral
29.
go back to reference Gong J, Su D, Shang J, et al. Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases: A meta-analysis. Medicine. 2019;98:e17091.CrossRefPubMedPubMedCentral
Gong J, Su D, Shang J, et al. Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases: A meta-analysis. Medicine. 2019;98:e17091.CrossRefPubMedPubMedCentral
30.
go back to reference Iosifidis E, Violaki A, Michalopoulou E, et al. Use of Tigecycline in pediatric patients with infections predominantly due to extensively drug-resistant gram-negative bacteria. J Pediatr Infect Dis Soc. 2017;6:123–8.
Iosifidis E, Violaki A, Michalopoulou E, et al. Use of Tigecycline in pediatric patients with infections predominantly due to extensively drug-resistant gram-negative bacteria. J Pediatr Infect Dis Soc. 2017;6:123–8.
31.
go back to reference Mastrolia MV, Galli L, De Martino M, Chiappini E. Use of Tigecycline in pediatric clinical practice. Expert Rev Anti Infect Ther. 2017;15:605–12.CrossRefPubMed
Mastrolia MV, Galli L, De Martino M, Chiappini E. Use of Tigecycline in pediatric clinical practice. Expert Rev Anti Infect Ther. 2017;15:605–12.CrossRefPubMed
32.
go back to reference Bakthavatchalam YD, Shankar A, Manokaran Y, Walia K, Veeraraghavan B. Can fosfomycin be an alternative therapy for infections caused by E. coli harbouring dual resistance: NDM and four-amino acid insertion in PBP3? JAC Antimicrob Resist. 2023;5:dlad016.CrossRefPubMedPubMedCentral
Bakthavatchalam YD, Shankar A, Manokaran Y, Walia K, Veeraraghavan B. Can fosfomycin be an alternative therapy for infections caused by E. coli harbouring dual resistance: NDM and four-amino acid insertion in PBP3? JAC Antimicrob Resist. 2023;5:dlad016.CrossRefPubMedPubMedCentral
33.
go back to reference Premachandran KP, Gopalakrishnan R, Ramasubramanian V, Krishnamurthy AC, Nambi PS. Clinical outcomes of patients treated with intravenous fosfomycin in a tertiary care hospital: an observational study. J Clin Infect Dis Soc. 2024;2:1–5.CrossRef
Premachandran KP, Gopalakrishnan R, Ramasubramanian V, Krishnamurthy AC, Nambi PS. Clinical outcomes of patients treated with intravenous fosfomycin in a tertiary care hospital: an observational study. J Clin Infect Dis Soc. 2024;2:1–5.CrossRef
34.
go back to reference Bakthavatchalam YD, Behera B, Shah A, et al. Tackling the unyielding: testing two novel approaches against NDM-producing enterobacterales and Pseudomonas aeruginosa isolates collected in India. Microbiol Spectr. 2025;13:e0049724.CrossRefPubMed
Bakthavatchalam YD, Behera B, Shah A, et al. Tackling the unyielding: testing two novel approaches against NDM-producing enterobacterales and Pseudomonas aeruginosa isolates collected in India. Microbiol Spectr. 2025;13:e0049724.CrossRefPubMed
35.
go back to reference Eliakim-Raz N, Lador A, Leibovici-Weissman Y, Elbaz M, Paul M, Leibovici L. Efficacy and safety of Chloramphenicol: joining the revival of old antibiotics? Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2015;70:979–96.CrossRefPubMed
Eliakim-Raz N, Lador A, Leibovici-Weissman Y, Elbaz M, Paul M, Leibovici L. Efficacy and safety of Chloramphenicol: joining the revival of old antibiotics? Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2015;70:979–96.CrossRefPubMed
36.
go back to reference Drapeau CMJ, Grilli E, Petrosillo N. Rifampicin combined regimens for gram-negative infections: data from the literature. Int J Antimicrob Agents. 2010;35:39–44.CrossRefPubMed
Drapeau CMJ, Grilli E, Petrosillo N. Rifampicin combined regimens for gram-negative infections: data from the literature. Int J Antimicrob Agents. 2010;35:39–44.CrossRefPubMed
37.
go back to reference Flannery DD, Chiotos K, Gerber JS, Puopolo KM. Neonatal multidrug-resistant gram-negative infection: epidemiology, mechanisms of resistance, and management. Pediatr Res. 2022;91:380–91.CrossRefPubMed
Flannery DD, Chiotos K, Gerber JS, Puopolo KM. Neonatal multidrug-resistant gram-negative infection: epidemiology, mechanisms of resistance, and management. Pediatr Res. 2022;91:380–91.CrossRefPubMed
38.
go back to reference Wu H, Harder C, Culley C. The 2016 clinical practice guidelines for management of hospital-acquired and ventilator-associated pneumonia. Can J Hosp Pharm. 2017;70:251–2.CrossRefPubMedPubMedCentral
Wu H, Harder C, Culley C. The 2016 clinical practice guidelines for management of hospital-acquired and ventilator-associated pneumonia. Can J Hosp Pharm. 2017;70:251–2.CrossRefPubMedPubMedCentral
39.
go back to reference Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of Cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21:226–40.CrossRefPubMed
Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of Cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21:226–40.CrossRefPubMed
40.
go back to reference Zheng D, Bergen PJ, Landersdorfer CB, Hirsch EB. Differences in fosfomycin resistance mechanisms between Pseudomonas aeruginosa and Enterobacterales. Antimicrob Agents Chemother. 2022;66:e01446–21.CrossRefPubMedPubMedCentral
Zheng D, Bergen PJ, Landersdorfer CB, Hirsch EB. Differences in fosfomycin resistance mechanisms between Pseudomonas aeruginosa and Enterobacterales. Antimicrob Agents Chemother. 2022;66:e01446–21.CrossRefPubMedPubMedCentral
41.
go back to reference Papp-Wallace KM, Zeiser ET, Becka SA, et al. Ceftazidime-avibactam in combination with fosfomycin: A novel therapeutic strategy against multidrug-resistant Pseudomonas aeruginosa. J Infect Dis. 2019;220:666–76.CrossRefPubMedPubMedCentral
Papp-Wallace KM, Zeiser ET, Becka SA, et al. Ceftazidime-avibactam in combination with fosfomycin: A novel therapeutic strategy against multidrug-resistant Pseudomonas aeruginosa. J Infect Dis. 2019;220:666–76.CrossRefPubMedPubMedCentral
Metadata
- Title
- Management of Carbapenem Resistant Gram-Negative Infections
- Author
-
Vidya Krishna
- Publication date
- 14-04-2025
- Publisher
- Springer India
- Keywords
- Carbapenem Antibiotic
Ceftazidime
Meropenem
Tigecycline
Aztreonam
Fosfomycin
Urinary Tract Infection - Published in
-
Indian Journal of Pediatrics
Print ISSN: 0019-5456
Electronic ISSN: 0973-7693 - DOI
- https://doi.org/10.1007/s12098-025-05537-3
Image Credits
Person in orange t-shirt using an e-cigarette/© licsiren / Getty Images / iStock (symbolic image with model)